期刊
NANOMEDICINE
卷 8, 期 5, 页码 849-856出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.13.68
关键词
block copolymer micelle; coating; colloidal iron-based nanomedicine; drug development; liposomal formulation; nanomedicine; nanosimilar; next-generation nanomedicine; regulatory science
Over the last three decades many first-generation nanomedicines have successfully entered routine clinical use and it is now important for medicines regulatory agencies to consider the mechanisms needed to ensure safe introduction of 'follow-on' nanomedicine products, 'nanosimilars'. Moreover, drug regulators need to ensure that 'next'-generation nanomedicines enter clinical development and consequently the market in a safe and timely way for the benefit of public health. Here we review recent European Medicines Agency activities that relate to the effective development and evaluation of nanomedicine products while keeping patient and consumer safety at the forefront.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据